NCT02873338Phase 2Completed

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2019-06Actual

Enrollment · participants75Actual

Source updated2023-09-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Acute Myeloid Leukemia

Treatments or interventions studied

Dociparstat sodiumDrugAlso known as 2-O, 3-O desulfated heparin, ODSH, PGX-100, CX-01, Dociparstat
IdarubicinDrugAlso known as Idamycin
CytarabineDrug

Primary outcomes · main study measures

Read the study measures

measure: Number of Subjects Who Achieved Morphologic Complete Remission; description: Morphologic complete remission (CR) was evaluated by International Working Group (IWG) criteria and defined as absolute neutrophil count (ANC) \>1000/microliter; platelet count \>100,000, \<5% blasts in bone marrow aspirate, no blasts with Auer rods, and no evidence of extramedullary disease.; timeFrame: During induction and re-induction phases of treatment (up to 60 days after the start of each treatment cycle)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history